REDWOOD CITY, California, Aug. 21, 2019 /PRNewswire/ -- Genomic Health today announced that, based on results from the prospective TAILORx1 and PlanB2 studies, the 16th St. Gallen International Breast ...

New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial ...

As the American Urological Association (AUA) annual meeting prepares to kick off on May 12, newly published prostate cancer guidelines recommend two tests to help clinicians and patients determine the ...

- Study in over 500 patients with node-negative or node-positive disease highlights impact of the test on treatment decisions, reducing potential over- and under-treatment and leading to a 23.5% net ...

Young patients with breast cancer ( 35 years): Single-institution study of 194 patients from India. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract does not include ...

Based on results presented at the ongoing San Antonio Breast Cancer Symposium, the gene panel was found to predict the risk of disease recurrence in women who had undergone breast conservation surgery ...

A cost-effectiveness analysis has found that Oncotype DX may not be economical to make clinical decisions on adjuvant radiation treatment in patients with DCIS. A part of precision medicine involves ...

The Oncotype DX Breast Recurrence Score® test, which has been used by over 1.5 million patients, indicates the likelihood of your cancer recurring based on the biology of your tumor. 1,2,3,4 It is ...

Please provide your email address to receive an email when new articles are posted on . Similar proportions of older women with node-negative and node-positive early breast cancer had Oncotype Dx ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score(R) ...